ROCKET PHARMACEUTICALS, INC. 8-K

What Happened
On March 27, 2026, Rocket Pharmaceuticals, Inc. filed an 8-K and issued a press release announcing that the U.S. Food and Drug Administration approved KRESLADI™ (marnetegragene autotemcel), an autologous hematopoietic stem cell–based gene therapy. The approval covers pediatric patients with severe leukocyte adhesion deficiency‑I (LAD‑I) due to biallelic variants in ITGB2 who do not have an available HLA‑matched sibling donor for allogeneic hematopoietic stem cell transplant. With the approval, the FDA also granted Rocket a Rare Pediatric Disease Priority Review Voucher (PRV). The company said it intends to evaluate strategic options to monetize the PRV to enhance financial flexibility and maximize shareholder value. The press release is included in the filing as Exhibit 99.1.

Key Details

• Filing date: March 27, 2026 (Form 8-K, Regulation FD disclosure).
• Product: KRESLADI™ (marnetegragene autotemcel), an autologous hematopoietic stem cell–based gene therapy.
• Indication: Pediatric patients with severe LAD‑I caused by biallelic ITGB2 variants without an available HLA‑matched sibling donor for allogeneic HSCT.
• FDA also granted a Rare Pediatric Disease Priority Review Voucher (PRV); Rocket plans to evaluate options to monetize the PRV.
• Press release attached as Exhibit 99.1 to the 8‑K.

Why It Matters
FDA approval makes KRESLADI an approved therapy for a defined rare pediatric population, which could form the basis for commercial sales and clinical use subject to Rocket’s launch and commercialization plans. The PRV is a transferable regulatory asset that the company says it may monetize; selling or using a PRV can provide meaningful near‑term financial flexibility. The 8‑K does not include launch timelines, sales forecasts or financial terms for any PRV monetization—investors should watch for follow‑on disclosures about commercialization plans, pricing, and potential revenue impacts.